Socioeconomic Differences in Preferences and Willingness-to-Pay for Insulin Delivery Systems in Type 1 and Type 2 Diabetes

2009 ◽  
Vol 11 (9) ◽  
pp. 567-573 ◽  
Author(s):  
Camila Guimarães ◽  
Carlo A. Marra ◽  
Lindsey Colley ◽  
Sabrina Gill ◽  
Scot Simpson ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Willingness To Pay ◽  
Insulin Delivery ◽  
Delivery Systems ◽  
Socioeconomic Differences

Development of a New Measure for Assessing Insulin Delivery Device Satisfaction in Patients with Type 1 and Type 2 Diabetes

2015 ◽  
Vol 17 (11) ◽  
pp. 773-779 ◽  
Author(s):  
William H. Polonsky ◽  
Lawrence Fisher ◽  
Danielle Hessler ◽  
Steven V. Edelman
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Delivery ◽  
Delivery Device

A valuation of patients' willingness-to-pay for insulin delivery in diabetes

2009 ◽  
Vol 25 (03) ◽  
pp. 359-366 ◽  
Author(s):  
Camila Guimarães ◽  
Carlo A. Marra ◽  
Lindsey Colley ◽  
Sabrina Gill ◽  
Scot H. Simpson ◽  
...  
Keyword(s):  
Willingness To Pay ◽  
Insulin Therapy ◽  
Blood Glucose Control ◽  
Insulin Delivery ◽  
Cross Sectional ◽  
Short Acting ◽  
Acting Insulin ◽  
Short Acting Insulin

Objectives:The aim of this study was to determine the insulin-delivery system and the attributes of insulin therapy that best meet patients' preferences, and to estimate patients' willingness-to-pay (WTP) for them.Methods:This was a cross-sectional discrete choice experiment (DCE) study involving 378 Canadian patients with type 1 or type 2 diabetes. Patients were asked to choose between two hypothetical insulin treatment options made up of different combinations of the attribute levels. Regression coefficients derived using conditional logit models were used to calculate patients' WTP. Stratification of the sample was performed to evaluate WTP by predefined subgroups.Results:A total of 274 patients successfully completed the survey. Overall, patients were willing to pay the most for better blood glucose control followed by weight gain. Surprisingly, route of insulin administration was the least important attribute overall. Segmented models indicated that insulin naïve diabetics were willing to pay significantly more for both oral and inhaled short-acting insulin compared with insulin users. Surprisingly, type 1 diabetics were willing to pay $C11.53 for subcutaneous short-acting insulin, while type 2 diabetics were willing to pay $C47.23 to avoid subcutaneous short-acting insulin (p< .05). These findings support the hypothesis of a psychological barrier to initiating insulin therapy, but once that this barrier has been overcome, they accommodate and accept injectable therapy as a treatment option.Conclusions:By understanding and addressing patients' preferences for insulin therapy, diabetes educators can use this information to find an optimal treatment approach for each individual patient, which may ultimately lead to improved control, through improved compliance, and better diabetes outcomes.

Willingness to Pay for Improvements in Chronic Long-Acting Insulin Therapy in Individuals With Type 1 or Type 2 Diabetes Mellitus

2011 ◽  
Vol 33 (9) ◽  
pp. 1258-1267 ◽  
Author(s):  
Andrew Lloyd ◽  
Beenish Nafees ◽  
Anthony H. Barnett ◽  
Simon Heller ◽  
Uffe J. Ploug ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Willingness To Pay ◽  
Insulin Therapy ◽  
Acting Insulin ◽  
Long Acting

scholarly journals The Use of Omnipod® 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes With Suboptimal Glycemic Management: From Injections to Closed-Loop Therapy

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A479-A479
Author(s):  
Bruce W Bode ◽  
Anne Peters ◽  
Anders L Carlson ◽  
Bonnie Dumais ◽  
Steven Lowen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Insulin Delivery ◽  
Outpatient Setting ◽  
Time In Range ◽  
Insulin Delivery System ◽  
Mean Glucose ◽  
Glycemic Management

Abstract Advances in automated insulin delivery (AID), integrating continuous glucose monitoring (CGM), insulin pump therapy, and dynamic insulin modulation, have mostly centered on type 1 diabetes. Very little data exists to characterize the use of AID in adults with type 2 diabetes in the outpatient setting despite the significant burden of disease. The increasing adoption of diabetes technology by this heterogenous population suggests that clinical evaluation of AID in type 2 diabetes is necessary. In this study, we seek to enroll adults with type 2 diabetes, previously on either multiple daily injections (MDI) or basal insulin only (pump naïve), both CGM users and CGM naïve, with A1C > 8%, to start AID using the tubeless, on-body Omnipod 5 system with insulin pod and Dexcom G6 sensor. This system has the novel feature1 of customizable glucose targets from 110-150mg/dL, which is useful for gradual reduction of mean glucose levels in patients acclimated to hyperglycemic ranges. In addition, the system adapts to the persistent hyperglycemia commonly seen in type 2 diabetes by increasing insulin delivery with each pod change. This feasibility study will enroll a minimum of 24 participants, following them through a 2-week baseline assessment and then an 8-week period of Omnipod 5 use in Automated Mode, all via the outpatient setting. To date, 3 participants have enrolled and are currently using the system: age (mean±SD) 54±12y, weight 79.7±9.0kg, baseline A1C 9.3±0.2% (range 9.1–9.5%), and duration of diabetes 18.3±12.4y. Previous anti-hyperglycemic agents including metformin and GLP-1R agonists were continued. Participants have used Omnipod 5 in Automated Mode ranging from 26 to 53 days. In the preliminary analysis of Automated Mode use, mean glucose of 194±33 mg/dL was achieved, corresponding to a glucose management indicator (GMI) of 8.0±0.8%. Time in range, 70-180mg/dL, was 49.0±19.2%, time <70mg/dL was 0.2±0.2%, >180mg/dL was 50.8±19.4%, and ≥250mg/dL was 19.3±15.6%. Average total daily insulin use was 77.9±41.4 units/day. In the most recent 14 days of use, GMI was further decreased to 7.6±0.5%, and time in range further increased to 57.6±14.1%. There have been no serious adverse events, including severe hypoglycemia, reported in over 110 person-days of system use to date. At completion, this study will provide a novel evaluation of the safety and effectiveness of AID in adults with type 2 diabetes with suboptimal glycemic management, despite the concomitant use of adjuvant anti-hyperglycemic agents. Reference: 1. Forlenza et. al. First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes. Diabetes Technol Ther 2021.

Type 2 Diabetes Overtakes Type 1 in Hispanic Girls

2008 ◽  
Vol 38 (15) ◽  
pp. 18
Author(s):  
SHERRY BOSCHERT
Keyword(s):  
Type 2 Diabetes
Sign in / Sign up

Export Citation Format

Share Document